Drugs / Measles Mumps and Rubella Combined Vaccine, Live
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05279248 | Aug 2021 → Dec 2022 | human papilloma virus infection, measles, mumps infectious disease, rubella | Zhejiang Provincial Center for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles Mumps and Rubella Combined Vaccine, Live | “The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles...” NCT05279248 ↗ |
| Known as | MMR | “The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles...” NCT05279248 ↗ |
| Modality | Vaccine | “Measles Mumps and Rubella Combined Vaccine, Live” NCT05279248 ↗ |